Zimmer raises sales forecast despite slower knee business
Zimmer Biomet reported Q3 sales of $2.06B, up 3.1% YoY, with knee sales down 3.1% but hip sales up 6%. The company raised its 2026 revenue growth forecast to 4.4-4.9%. CEO Ivan Tornos attributed knee sales decline to commercial execution and market competition, not a broader slowdown, according to the company. Analysts, however, suggest market-related weakness. Zimmer plans to file an FDA application for a new surgical robot, acquired via Monogram Technologies, expecting a 2027 launch.
How this was made
The 30-second read
Why it matters
Guidance raise and robot development could drive medium‑term revenue growth, while short‑term knee sales weakness may limit immediate upside.
Market read
The guidance upgrade is a fresh, material development for a large‑cap medtech stock, offering a clear trading catalyst.
What to watch
Execution challenges in the knee segment and competitive pressure could temper upside.
Background
Zimmer Biomet reported Q3 sales of $2.06 bn, with knee implant sales down 3.1% YoY but hip sales up 6%. The company is transitioning to a dedicated salesforce and plans a new surgical robot launch in 2027.
Ticker impact
Zimmer Biomet raised its 2026 revenue growth guidance to 4.4%-4.9% after reporting Q3 results, indicating improved outlook.
upward pressure as investors price in higher growth expectations
Guidance upgrades are a primary catalyst; the company is a large‑cap medtech with a material revenue base.
Market effects
May lift other orthopedics and medtech peers as market reassesses growth outlook.
U.S. healthcare sector could see modest gains.
Limited to medtech investors; no broad macro impact.
Counterpoint
Skeptics may argue knee sales slowdown signals broader demand weakness.
Key entities
- companyZimmer Biomet
Orthopedics firm that raised its 2026 revenue guidance.
- executiveIvan Tornos
CEO of Zimmer Biomet who defended the outlook.
